Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs

被引:55
作者
Nishimuta, Haruka [1 ]
Nakagawa, Tetsuya [1 ]
Nomura, Naruaki [1 ]
Yabuki, Masashi [1 ]
机构
[1] Dainippon Sumitomo Pharma Co Ltd, Pharmacokinet Res Lab, Suita, Osaka 5640053, Japan
关键词
CYP1A; CYP2C; CYP2D; CYP2J; CYP3A; intestine; liver; microsomes; DRUG-METABOLISM; IN-VITRO; MESSENGER-RNAS; EXPRESSION; LIVER; CYP3A; VIVO; P450; PREDICTION; ENZYMES;
D O I
10.3109/00498254.2013.787155
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Prediction of human pharmacokinetics might be made more precise by using species with similar metabolic activities to humans. We had previously reported the species differences in intestinal and hepatic metabolic activities of 43 cytochrome P450 (CYP) substrates between cynomolgus monkeys and humans. However, the species differences between humans and rats or dogs had not yet been determined using comparable data sets with sufficient number of compounds. 2. Here, we investigated metabolic stabilities in intestinal and liver microsomes obtained from rats, dogs and humans using 43 substrates of human CYP1A2, CYP2J2, CYP2C, CYP2D6 and CYP3A. 3. Hepatic intrinsic clearance (CLint) values for most compounds in dogs were comparable to those in humans (within 10-fold), whereas in rats, those for the human CYP2D6 substrates were much higher and showed low correlation with humans. In dog intestine, as with human intestine, CLint values for almost all human CYP1A2, CYP2C, CYP2D6 substrates were not determined because they were very low. Intestinal CLint values for human CYP3A substrates in rats and dogs appeared to be lower for most of the compounds and showed moderate correlation with those in humans. 4. In conclusion, dogs showed the most similar metabolic activity to humans.
引用
收藏
页码:948 / 955
页数:8
相关论文
共 30 条
[1]   Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats [J].
Aiba, T ;
Takehara, Y ;
Okuno, M ;
Hashimoto, Y .
PHARMACEUTICAL RESEARCH, 2003, 20 (05) :745-748
[2]  
Chow T, 1999, DRUG METAB DISPOS, V27, P188
[3]   ANIMAL SCALE-UP [J].
DEDRICK, RL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1973, 1 (05) :435-460
[4]   Assessment of CYP1A2 activity in clinical practice: Why, how, and when? [J].
Faber, MS ;
Jetter, A ;
Fuhr, U .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 97 (03) :125-134
[5]   Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR [J].
Hiroi, T ;
Imaoka, S ;
Chow, T ;
Funae, Y .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1998, 1380 (03) :305-312
[6]   Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches [J].
Hosea, Natilie A. ;
Collard, Wendy T. ;
Cole, Susan ;
Maurer, Tristan S. ;
Fang, Rick X. ;
Jones, Hannah ;
Kakar, Shefali M. ;
Nakai, Yasuhiro ;
Smith, Bill J. ;
Webster, Rob ;
Beaumont, Kevin .
JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (05) :513-533
[7]  
HOUSTON JB, 1994, BIOCHEM PHARMACOL, V47, P1469
[8]   Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data [J].
Iwatsubo, T ;
Hirota, N ;
Ooie, T ;
Suzuki, H ;
Shimada, N ;
Chiba, K ;
Ishizaki, T ;
Green, CE ;
Tyson, CA ;
Sugiyama, Y .
PHARMACOLOGY & THERAPEUTICS, 1997, 73 (02) :147-171
[9]   Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates [J].
Komura, Hiroshi ;
Iwaki, Masahiro .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (05) :1775-1800
[10]   Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobioties: A compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families [J].
Lewis, DFV .
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (19) :1955-1972